Covid-19 Leaves Lasting Impact on Hematology at ASH 2020 Conference
Under the heavy shadow of the Covid-19 pandemic, last week’s annual conference of the American…
Under the heavy shadow of the Covid-19 pandemic, last week’s annual conference of the American…
Paris attracts millions of tourists to see some of the world’s most iconic monuments: the…
An off-the-shelf, gene edited CAR T-cell therapy, developed by the French biotech Cellectis, could be…
CAR-T therapy has been hailed as a cure for cancer, but what really is this…
Here’s the list of the European biotech companies, both public and private, that are worth…
Cellectis is developing a new type of chimeric antigen receptor that could improve the production…
Cellectis has raised $164M (€132M) in a follow-on offering to further develop its CAR-T technology in…
Despite all the hype, CRISPR is still not in the clinic as a standalone therapy…
Update (16/02/2018): On top of the European patent it got last July, Cellectis now also…
Most CAR-T stocks rose on the news that Big Biotech Celgene has plans to acquire…
Here's a closer look at the French biotech ecosystem in 2017, which remains one the…
Still catching up on news? We've picked out the most exciting things that happened besides…